A drug used to prevent or treat stem cell allograft rejection and graft versus host disease by suppressing the immune system of the transplant recipient.
For graft-versus-host disease (GVHD ) prophylaxis, all patients received cyclosporin A (CSA) and, in addition, short-course methotrexate (MTX) was administered to the recipients of non-T-cell-depleted related and mismatched unrelated grafts.